DK0730740T3 - Kinasereceptoraktiveringsassay - Google Patents

Kinasereceptoraktiveringsassay

Info

Publication number
DK0730740T3
DK0730740T3 DK95903133T DK95903133T DK0730740T3 DK 0730740 T3 DK0730740 T3 DK 0730740T3 DK 95903133 T DK95903133 T DK 95903133T DK 95903133 T DK95903133 T DK 95903133T DK 0730740 T3 DK0730740 T3 DK 0730740T3
Authority
DK
Denmark
Prior art keywords
receptor
cells
construct
tyrosine kinase
pct
Prior art date
Application number
DK95903133T
Other languages
Danish (da)
English (en)
Inventor
Paul J Godowski
Melanie R Mark
Michael Daniel Sadick
Wai Lee Tan Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/170,558 external-priority patent/US6001621A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0730740T3 publication Critical patent/DK0730740T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95903133T 1993-11-23 1994-11-18 Kinasereceptoraktiveringsassay DK0730740T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15756393A 1993-11-23 1993-11-23
US08/170,558 US6001621A (en) 1993-11-23 1993-12-20 Protein tyrosine kinases
US28630594A 1994-08-05 1994-08-05
PCT/US1994/013329 WO1995014930A1 (en) 1993-11-23 1994-11-18 Kinase receptor activation assay

Publications (1)

Publication Number Publication Date
DK0730740T3 true DK0730740T3 (da) 1998-09-28

Family

ID=27388031

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95903133T DK0730740T3 (da) 1993-11-23 1994-11-18 Kinasereceptoraktiveringsassay

Country Status (12)

Country Link
US (3) US6025145A (ja)
EP (1) EP0730740B1 (ja)
JP (1) JP3442784B2 (ja)
AT (1) ATE163231T1 (ja)
AU (1) AU698975B2 (ja)
CA (1) CA2175892C (ja)
DE (1) DE69408541T2 (ja)
DK (1) DK0730740T3 (ja)
ES (1) ES2116066T3 (ja)
GR (1) GR3026430T3 (ja)
HK (1) HK1008440A1 (ja)
WO (1) WO1995014930A1 (ja)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711341A4 (en) * 1993-07-29 2001-12-19 Cor Therapeutics Inc METHODS OF DETERMINING THE FUNCTION OF A RECEPTOR
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU727606B2 (en) 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
FR2776661B1 (fr) * 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US6253441B1 (en) * 1999-04-16 2001-07-03 General Electric Company Fabrication of articles having a coating deposited through a mask
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
CA2378481A1 (en) * 1999-08-06 2001-02-15 Institut Pasteur A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate
US6406869B1 (en) * 1999-10-22 2002-06-18 Pharmacopeia, Inc. Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
KR100823764B1 (ko) 2000-06-22 2008-04-21 제넨테크, 인크. 아고니스트 안티-티알케이-씨 모노클로날 항체
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6919173B2 (en) 2001-09-10 2005-07-19 Meso Scale Technologies, Llc. Assay buffer, compositions containing the same, and methods of using the same
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
AU2003300397A1 (en) * 2002-12-23 2004-07-22 Rinat Neuroscience Corp. Methods for treating taxol-induced sensory neuropathy
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
PT2270048E (pt) * 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
PT1454992E (pt) * 2003-03-07 2006-09-29 Ist Naz Stud Cura Dei Tumori Ensaio de quinase do linfoma anaplastico, reagentes e composicoes
EP1606409B1 (en) 2003-03-19 2010-09-01 Biogen Idec MA Inc. Nogo receptor binding protein
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
HUE037549T2 (hu) 2004-04-07 2018-09-28 Rinat Neuroscience Corp Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
JP4960865B2 (ja) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄に関連する状態の処置
KR20070038557A (ko) 2004-07-22 2007-04-10 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1662258A1 (en) * 2004-11-25 2006-05-31 Sirenade Pharmaceuticals AG A substrate free in vitro protein kinase assay
ZA200706017B (en) 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
US7189522B2 (en) * 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) * 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
KR101245462B1 (ko) 2005-07-08 2013-03-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｐ35 항체 및 그의 용도
JP2009516167A (ja) * 2005-11-11 2009-04-16 ロジャー・ウィリアムズ・ホスピタル 癌処置における予測マーカーとしてのｐ６６−ｓｈｃ
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
ATE539165T1 (de) 2007-10-19 2012-01-15 Becton Dickinson Co Verfahren zum nachweis von beta-lactamase
KR101658245B1 (ko) * 2007-10-24 2016-09-22 바이오마커 스트레터지스 엘엘씨 개선된 세포 분석용 방법 및 장치
WO2009058908A2 (en) 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
EP2217697B1 (en) * 2007-11-08 2015-06-10 Biogen MA Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
SI2250279T1 (sl) 2008-02-08 2016-10-28 Medimmune, Llc Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
EP2315779A2 (en) * 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
WO2010047868A1 (en) * 2008-08-18 2010-04-29 Discoverx Corporation Receptor tyrosine kinase assays
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
WO2010047778A1 (en) 2008-10-20 2010-04-29 Becton Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular microorganism targets
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN106062560A (zh) 2014-03-31 2016-10-26 默克专利股份公司 使用特异性抗体检测蛋白质修饰的方法
EP3578635B1 (en) 2014-04-02 2021-11-03 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311889A1 (de) * 1983-03-31 1984-10-11 Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach Verfahren zur irreversiblen bindung von protein an polystyroloberflaechen unter erhaltung der biologischen aktivitaet, so erhaltene polystyroloberflaechen und ihre verwendung
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
CA2128722A1 (en) * 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
DE69334053T2 (de) * 1992-04-10 2007-01-04 Dana-Farber Cancer Institute, Inc., Boston Immunnachweis eines aktivierungszustandsspezifischen phosphoproteins
AU6117294A (en) * 1993-02-16 1994-09-14 Auckland Uniservices Limited Developmental tyrosine kinases and their ligands

Also Published As

Publication number Publication date
US5891650A (en) 1999-04-06
CA2175892A1 (en) 1995-06-01
CA2175892C (en) 2000-03-07
ATE163231T1 (de) 1998-02-15
DE69408541T2 (de) 1998-08-06
GR3026430T3 (en) 1998-06-30
EP0730740A1 (en) 1996-09-11
US6025145A (en) 2000-02-15
JP3442784B2 (ja) 2003-09-02
JPH09505889A (ja) 1997-06-10
AU1210895A (en) 1995-06-13
AU698975B2 (en) 1998-11-12
EP0730740B1 (en) 1998-02-11
US5914237A (en) 1999-06-22
DE69408541D1 (de) 1998-03-19
ES2116066T3 (es) 1998-07-01
WO1995014930A1 (en) 1995-06-01
HK1008440A1 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
DK0730740T3 (da) Kinasereceptoraktiveringsassay
Wilce et al. Physicochemical basis of amino acid hydrophobicity scales: evaluation of four new scales of amino acid hydrophobicity coefficients derived from RP-HPLC of peptides
CN1703624B (zh) 用于检测mhc-ⅰ类和mhc-ⅱ类结合肽的方法和体系
TR200002257T2 (tr) Nükleer reseptör ligandları ve ligand bağlanma domainleri.
DE69334100D1 (de) Elk ligand, ein cytokin
ATE217344T1 (de) Antigen bindende peptide (abtides) aus peptidbibliotheken
HUP0104750A2 (hu) OPG fúziósfehérje összetételek és eljárások
EP0873998A3 (en) Receptor protein and its use
US4703016A (en) Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
MERCIER et al. Structure primaire du caséinomacropeptide de la caséine κB1 bovine
CA2279881A1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
DE59914768D1 (de) Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
Ihara et al. [3H] BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype
Irngartinger et al. 06. CHARGE, SPIN AND MOMENTUM DENSITI ES C-155
Chin et al. The use of tributylphosphine and 4-(aminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole in the study of protein sulfhydryls and disulfides
Proniewicz et al. Role of Phe‐D5 isotopically labeled analogues of bradykinin on elucidation of its adsorption mode on Ag, Au, and Cu electrodes. Surface‐enhanced Raman spectroscopy studies
Moss et al. Solubility and posttranslational regulation of GP130/F11--a neuronal GPI-linked cell adhesion molecule enriched in the neuronal membrane skeleton.
ATE286251T1 (de) Immuntest unter verwendung von partikeln mit kaseinumhüllungen
Bähr et al. Interaction of the effector domain of MARCKS and MARCKS-related protein with lipid membranes revealed by electric potential measurements
CA2294969A1 (en) Surfaces coated with streptavindin/avidin
WO2003000732A3 (en) Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
JP2000214165A5 (ja)
AU8857991A (en) Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides
Murata et al. Binding of immunoglobulin molecules to preadsorbed protein A layers as observed by surface forces measurements
Dybkaer Quantities and units for biological reference materials used with in vitro diagnostic measuring systems for antibodies